I. E. L. M. Kuppens

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

I. E. L. M. Kuppens, Els O. Witteveen, Roxanne C. Jewell et al. · Clinical Cancer Research · 2007 · 174 citations

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)

I. E. L. M. Kuppens, Tessa M. Bosch, M. J. van Maanen et al. · Cancer Chemotherapy and Pharmacology · 2004 · 85 citations

Medicinal Chemistry, Oral Bioavailability, Pharmaceutical Science +6

Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry

I. E. L. M. Kuppens, M. J. van Maanen, Hilde Rosing et al. · Biomedical Chromatography · 2004 · 58 citations

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

Nadja E. Schoemaker, I. E. L. M. Kuppens, Vladimir Moiseyenko et al. · British Journal of Cancer · 2004 · 34 citations · Full text

Phase I study of an oral formulation of irinotecan administered daily for 14�days every 3�weeks in patients with advanced solid tumours

Nadja E. Schoemaker, I. E. L. M. Kuppens, W.W. ten Bokkel Huinink et al. · Cancer Chemotherapy and Pharmacology · 2004 · 29 citations

Oncology, Pharmacology, Advanced Solid Tumours +8